Stifel: Now's The Time To Buy These 3 Stocks
In a recent report, Stifel analysts gave their bullish analysis of several stocks. Here’s a breakdown of what the analysts had to say about three of their Buy-rated names.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
Analysts see “blockbuster potential” for Jazz’s defibrotide drug that Jazz acquired full rights to in 2014. The drug, used to treat hepatic veno-occlusive disease, has already launched in Europe and is working its way down the U.S. regulatory pathway.
Analysts believe that that defibrotide will see expanded uses in the future and that the drug could eventually surpass the value of Jazz’s flagship drug, Xyrem.
Analysts feel that the market is not fully appreciating the potential of defibrotide, and they name Jazz as a top pick and place a $225.00 target on the stock.
Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH)
The major case analysts make for Norwegian Cruise Line is a valuation case. Analysts note that the stock currently trades at just about 12x their 2016 earnings per share estimates for the company. Stifel is predicting 20 percent earnings growth for the company in each of the next three years.
Norwegian Cruise's stock jumped by more than 7 percent on Wednesday after Tuesday’s earnings beat, and Stifel sees more even more upside to come.
The firm has a Buy rating on the stock and a $49.00 price target.
WellCare Health Plans, Inc. (NYSE: WCG)
After a shaky past that includes wild swings in share price, an FBI raid and other drama, Stifel analysts are convinced that WellCare finally has a management team that understands the importance of both executing the company’s business plan and communicating clearly with shareholders.
Analysts predict that WellCare’s revenue and earnings will double in the next few years.
Stifel currently has a Buy rating on WellCare and a $100.00 price target on the stock.
Latest Ratings for JAZZ
|Aug 2016||Janney Capital||Initiates Coverage on||Neutral|
|Aug 2016||Deutsche Bank||Maintains||Buy|
|Jun 2016||BMO Capital||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.